Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

The STATUS Trial

Clinical Trial Title: 
The STATUS trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAGE-547 injection in the treatment of subjects with super-refractory status epilepticus (SRSE).
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Sebastian Pollandt, MD
Clinical Trial Protocol Description: 

The purpose of this study is to evaluate the efficacy and safety of an investigational medicine compared to placebo for the treatment of super-refractory status epilepticus. This is a multicenter trial seeking to recruit 140 patients. The treatment will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have failed to respond to the administration of at least one first-line agent (e.g., benzodiazepine or other emergent initial AED treatment).
  • Have failed to respond to at least one second-line agent (e.g., phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control AED.

You will be excluded from the study if any of the following criteria apply to you:

  • Have certain medical conditions.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Contact Phone: 
(312) 563-2741
Contact Name: 
Raquel Garcia-Cano